Q-omics provides the consensus-scored MTATP6P11 profile across patient tissues and cancer cell-line models. MTATP6P11 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MTATP6P11 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MTATP6P11 RNA expression shows 10,709 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, LUAD, and ESCA as cancer lineages where MTATP6P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P11 survival associations across molecular data types. MTATP6P11 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P11 RNA expression–survival associations across cancer types. High MTATP6P11 expression shows unfavorable associations in CHOL, DLBC, PAAD and LUSC, but favorable associations in BLCA and GBM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify BLCA as the clearest survival context for MTATP6P11 RNA expression.
This table summarizes MTATP6P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P11 shows lower tumor expression in LUAD, LUSC and KIRP. The LUAD box plot shows higher MTATP6P11 RNA expression in normal versus tumor tissue (log2 FC = −0.097, t-test p = .049).
This table shows molecular features associated with MTATP6P11 in patient tissues and cancer cell lines. In patient samples, MTATP6P11 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
